Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy

Alicia McDonald, Manish Vira, Vonn Walter, Jing Shen, Jay Raman, Martin G. Sanda, Dattatraya Patil, Emanuela Taioli

Research output: Contribution to journalArticle

Abstract

Background: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. Methods: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. Results: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. Conclusion: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.

Original languageEnglish (US)
Pages (from-to)961-968
Number of pages8
JournalProstate
Volume79
Issue number9
DOIs
StatePublished - Jun 15 2019

Fingerprint

MicroRNAs
Prostatic Neoplasms
Biopsy
Neoplasm Grading
Prostate-Specific Antigen
Tumor Biomarkers
Serum
Age Groups
Biomarkers
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

McDonald, Alicia ; Vira, Manish ; Walter, Vonn ; Shen, Jing ; Raman, Jay ; Sanda, Martin G. ; Patil, Dattatraya ; Taioli, Emanuela. / Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. In: Prostate. 2019 ; Vol. 79, No. 9. pp. 961-968.
@article{b389a67d19344efe93624d3e2bcf96e6,
title = "Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy",
abstract = "Background: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. Methods: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. Results: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. Conclusion: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.",
author = "Alicia McDonald and Manish Vira and Vonn Walter and Jing Shen and Jay Raman and Sanda, {Martin G.} and Dattatraya Patil and Emanuela Taioli",
year = "2019",
month = "6",
day = "15",
doi = "10.1002/pros.23803",
language = "English (US)",
volume = "79",
pages = "961--968",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "9",

}

Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. / McDonald, Alicia; Vira, Manish; Walter, Vonn; Shen, Jing; Raman, Jay; Sanda, Martin G.; Patil, Dattatraya; Taioli, Emanuela.

In: Prostate, Vol. 79, No. 9, 15.06.2019, p. 961-968.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy

AU - McDonald, Alicia

AU - Vira, Manish

AU - Walter, Vonn

AU - Shen, Jing

AU - Raman, Jay

AU - Sanda, Martin G.

AU - Patil, Dattatraya

AU - Taioli, Emanuela

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Background: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. Methods: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. Results: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. Conclusion: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.

AB - Background: MicroRNAs (miRNAs or miR-) have been linked to factors associated with aggressive prostate cancer such as biochemical recurrence and metastasis. We investigated whether circulating miRNAs in plasma could be used as diagnostic biomarkers for more aggressive prostate cancer at prostate biopsy. Methods: Men, aged 40 years and above, newly diagnosed with prostate cancer were categorized into two risk groups, low-grade (Gleason score, 6 or 7 [3 + 4] and serum prostate-specific antigen [PSA], <20 ng/mL) and high-grade (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) prostate cancers. The limma R package was used to compare the expression of miRNAs in plasma between the two risk groups, adjusting for age. Results: There were 66 men, aged 46-86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. There were lower expressions of miR-28, miR-100, miR-942, and miR-28-3p, and higher expressions of miR-708, miR-1298, miR-886-3p, miR-374, miR-376c, miR-202, miR-128a, and miR-185 in high-grade compared to low-grade prostate cancer cases at biopsy, after adjusting for age (P < 0.05). These differences were no longer statistically significant after adjusting the P values for multiple comparisons. Conclusion: There was no circulating miRNA associated with high-grade prostate cancer at biopsy after adjusting for age and multiple comparisons. Nevertheless, relationships between these circulating miRNAs and high-grade prostate cancer were observed, which suggest them as promising prostate cancer biomarkers. Further investigation in a larger cohort may provide insight into their diagnostic potential for aggressive prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85065791734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065791734&partnerID=8YFLogxK

U2 - 10.1002/pros.23803

DO - 10.1002/pros.23803

M3 - Article

VL - 79

SP - 961

EP - 968

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 9

ER -